ScottKopetzMDPhD

Oncology • Houston, TX

Gastrointestinal Medical Oncology at MD Anderson Cancer Center

Join to view full profile

Dr. Kopetz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kopetz's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Education & Training

University of Texas, Graduate School of Biomedical SciencesPhD, Cancer Biology, 2005 - 2009
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
Duke University HospitalResidency, Internal Medicine, 2001 - 2004
Johns Hopkins University School of MedicineClass of 2001

Certifications & Licensure

FL State Medical License 2021 - Present
AZ State Medical License 2022 - 2027
TN State Medical License 2022 - 2026
TX State Medical License 2004 - 2026
AL State Medical License 2022 - 2025
GA State Medical License 2022 - 2025
MS State Medical License 2022 - 2025
OK State Medical License 2020 - 2025
WA State Medical License 2022 - 2025
LA State Medical License 2022 - 2024
NC State Medical License 2001 - 2004
Join now to see all

Clinical Trials

Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer Start of enrollment: 2006 Feb 01
Terminated
Phase 3
Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients Start of enrollment: 2005 Jan 01
Completed
Phase 2
FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer Start of enrollment: 2007 Apr 23
Completed
Phase 1
Colorectal Cancer Umbrella Protocol - Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC Program) Screening Protocol Start of enrollment: 2010 Aug 01
Completed
Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery Start of enrollment: 2013 Mar 01
Completed
Phase 2
S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer Start of enrollment: 2014 Nov 01
Completed
Phase 2
Sym004 Versus Futuximab or Modotuximab in Patients With mCRC Start of enrollment: 2018 Nov 29
Terminated
Phase 2
Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer Start of enrollment: 2019 Oct 29
Active, not recruiting
Phase 2
Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer Start of enrollment: 2019 Jul 22
Active, not recruiting
Phase 1
DAILY: Vitamin D, Aspirin, ExercIse, Low Saturated Fat Foods StudY in Colorectal Cancer Patients With Minimal Residual Disease Start of enrollment: 2021 Oct 12
Recruiting
Not Applicable
Roles: Contact, Principal Investigator
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) Start of enrollment: 2022 Aug 04
Recruiting
Phase 1
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Mutational and co-mutational landscape of early onset colorectal cancer.
Jumanah Yousef Alshenaifi, Guglielmo Vetere, Giulia Maddalena, Mahmoud Yousef, Michael G White
Biomarkers. 2025-01-09
Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy.
Akram Yazdani, Heinz-Josef Lenz, Gianluigi Pillonetto, Raul Mendez-Giraldez, Azam Yazdani
Communications Medicine. 2025-01-08
Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients WithWild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial.
Kanwal Pratap Singh Raghav, Katherine A Guthrie, Benjamin Tan Jr, Crystal S Denlinger, Marwan Fakih
Journal of Clinical Oncology. 2025-01-06

Journal Articles

Anti-EGFR Resistant Clones Decay Exponentially After Progression: Implications for Anti-EGFR Re-Challenge
B Kee, N Garg, M J Overman, V K Morris, B Johnson, J Wu, J H Strickler, S Kopetz, X Liu, D S Hong, Annals of Oncology
Colorectal Premalignancy Is Associated with Consensus Molecular Subtypes 1 and 2
L M Ellis, P M Lynch, J A Willis, S Kopetz, Annals of Oncology
DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway
Scott Kopetz, Michael T Tetzlaff, Michael J Overman, Huamin Wang, Clinical Cancer Research

Press Mentions

U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal CancerDecember 20th, 2024
AmMax Bio and MD Anderson Announce Agreements to Advance Development of AMB-066 in Colorectal Cancer Patients with Minimal Residual DiseaseDecember 10th, 2024
Groundbreaking Clinical Trial Cures Cancer in 100% of PatientsNovember 20th, 2024
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member